1st Edition

Introduction to Market Access for Pharmaceuticals

Edited By Mondher Toumi Copyright 2017
    204 Pages 25 B/W Illustrations
    by CRC Press

    204 Pages
    by CRC Press

    Market access is the fourth hurdle in the drug development process and the primary driver for global income of any new drug. Without a strategy in place for pricing, showing value for effectiveness and an understanding of the target purchasers’ needs, the drug will fail to reach its intended market value. Introduction to Market Access for Pharmaceuticals is based on an accredited course in this area, taken from the European Market Access University Diploma (EMAUD), and is affiliated with Aix Marseille University.

    Key Features:

  • The first guide to market access for pharmaceuticals based on tested teaching materials
  • Addresses both pharmaceutical and vaccine products
  • Includes case studies and scenarios
  • Covers market access consdierations for Western Europe, the USA, Japan and China
  • Explains the impact the changing healthcare market will have on your product
  • Chapter 1: Health as a Good

    Chapter 2: Decision-Making in Public Health

    Chapter 3: Definition and Concepts

    Chapter 4: HTA Decision Analysis framework

    Chapter 5: Early HTA Advice

    Chapter 6: Overview of Market Access Agreements

    Chapter 7: External Reference Pricing

    Chapter 8: Gap between Payers and Regulators

    Chapter 9: Early Access Programs

    Chapter 10: Market Access of Orphan Drugs

    Chapter 11: Market Access of Vaccines in Developed Countries

    Chapter 12: France

    Chapter 13: Germany

    Chapter 14: Italy

    Chapter 15: Spain

    Chapter 16: Sweden

    Chapter 17: United Kingdom

    Chapter 18: The United States

    Chapter 19: Japan

    Chapter 20: China


    Mondher Toumi is M.D. by training, M.Sc. in Biostatistics, and in Biological Sciences (option pharmacology) and Ph.D. in Economic Sciences. Mondher Toumi is Professor of Public Health at Aix-Marseille University. After working for 12 years as Research Manager in the department of pharmacology at the University of Marseille, he joined the Public Health Department in 1993. In 1995 he embraces a carrier in the pharmaceutical industry for 13 years. Toumi was appointed Global Vice President at Lundbeck A/S in charge of health economics, outcome research, pricing, market access, epidemiology, risk management, governmental affairs and competitive intelligence. In 2008, he founded Creativ-Ceutical, an international consulting firm dedicated to support health industries and authorities in strategic decision-making. In February 2009 he was appointed Professor at Lyon I University in the Department of Decision Sciences and Health Policies. The same year, he was appointed Director of the Chair of Public Health and Market Access. He launched the first European University Diploma of Market Access (EMAUD) an international course already followed by almost 350 students. Additionally, he recently created the Market Access Society to promote education, research and scientific activities at the interface of market access, HTA, public health and health economic assessment. He is editor in Chief of the Journal of Market Access and Health Policy (JMAHP) which was just granted PubMed indexation. Toumi is also visiting Professor at Beijing University (Third Hospital). He is a recognized expert in health economics and an authority on market access and risk management. He has more than 250 scientific publications and communications, and has contributed to several books.